Key facts
- This page summarizes Louis G. Lange's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Mar 2026, 20:58.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Exercise of in-the-money or at-the-money derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Exercise of in-the-money or at-the-money derivative security
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Footnote F2
The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.